Abstract: The invention provides a SHINC-3 polynucleotide, which can be a nucleic acid encoding all or a portion of a SHINC-3 protein, or a complementary polynucleotide or antisense polynucleotide. In another aspect, the invention provides a SHINC-3 polypeptide, which can be a full-length SHINC-3 protein or a fragment thereof or an analog or homolog thereof. Desirably, the SHINC-3 polypeptide modulates apoptosis. In another aspect, the invention provides an antibody that specifically binds a SHINC-3 polypeptide. In another aspect, the invention provides diagnostic methods. For example, the method affords a method for identifying compounds that modulate apoptosis. In another aspect, the invention provides a method for detecting or evaluating the prognosis of a cancer. In another aspect, the invention provides diagnostic compositions for detection of cancer.

Abstract: Disclosed herein are phenylalanine derivative compounds of the following formula W—Y—(AA)n—Z wherein Y is a phenylalanyl radical, AA is an amino acid, n is an integer of 1 to 15, and substituent variables W and Z are as described herein. The compounds can be used to inhibit SH2 binding with phosphoproteins, and to inhibit proliferation of tumor cells.

Abstract: A gene that is a positive mediator of tumor growth and metastasis in certain cancer types is provided. This gene and corresponding polypeptide have diagnostic and therapeutic application for detecting and treating cancers that involve expression of SCC-S2 such as renal, ovarian, head and neck, breast, prostate, brain, chronic myelogenous leukemia, lung, lymphoblastic leukemia, and colorectal adenocarcinoma cells.

Abstract: The present invention provides 4-substituted-2-azetidinone compounds, bicyclic 2-5-diketopiperazine compounds, and pharmaceutical compositions thereof that are potent, safe and effective neuroprotective agents. Due to their strong central nervous system (CNS) activity, the compounds can be used to enhance memory and to treat a variety of neurological disorders. The compounds are particularly useful for treating neurological disorders caused by, or associated with, CNS trauma.

Abstract: A targeted vector allowing enhanced gene transfer to human hepato-cellular carcinoma (HCC1) cells in vitro was developed using cationic liposomes covalently conjugated with the mAb AF-20. This high affinity antibody recognizes a rapidly internalized 180 kDa cell surface glycoprotein which is abundantly expressed on the surface of human HCC and other cancer cells. Quantitative binding analysis of liposomes with target cells by flow cytometry showed specific association of mAb-targeted liposomes with human HCC cells. Using mAb-targeted cationic liposomes containing 20% DOTAP, in the presence or absence of serum, gene expression in HuH-7 cells was enhanced up to 40-fold as compared to liposomes conjugated with an isotype-matched non-relevant control antibody. Transfection specificity was not observed in a control cell line that does not express the antigen recognized by mAb AF-20.

Abstract: The present invention provides methods of preparing an antibody- or antibody fragment-targeted cationic immunoliposome or polymer complex comprising (a) preparing an antibody or antibody fragment; (b) mixing said antibody or antibody fragment with a cationic liposome to form a cationic immunoliposome or with a cationic polymer to form a polyplex; and (c) mixing said cationic immunoliposome or said polyplex with a therapeutic or diagnostic agent to form said antibody- or antibody fragment-targeted cationic immunoliposome or polymer complex. The present invention also provides cationic immunoliposome or polymer complexes produced by such methods and compositions comprising such complexes. The present invention also provides methods for treating various diseases and disorders, including cancers, by administering the complexes and compositions of the invention to a patient.

Abstract: The specification is directed to a method of diagnosing whether a subject is predisposed to an adverse reaction to one or more pharmaceutical agents which may induce a prolonged QT interval or acquired LQTS in that individual. The diagnosis is genetic analysis of at least two polymorphisms or mutations which the individual may have, which are associated with an increased risk for prolonged QT intervals or Torsades de Pointes (TdP). Genetic screening for determining the predisposition of prolonged QT intervals induced by a pharmaceutical agent is performed by identifying genetic polymorphisms or mutations located in at least two classes of genes, wherein the genes are (1) LQT genes, (2) altered sensitivity genes (e.g., MiRP1) or (3) increased exposure genes (e.g., MDR genes or P450 cytochrome genes). The specification is also directed to compositions and kits for determining such predispositions to adverse drug reactions.

Abstract: The present invention provides methods of treating a portion of a subterranean formation, one of which includes: providing a gelled nonaqueous treatment fluid that comprises a nonaqueous base fluid and a difunctional gelling agent that comprises a polyvalent metal salt of a bisorganophosphinic acid, a polyvalent metal salt of a bisorthophosphoric acid diester, and/or a polyvalent metal salt of a bisorganophosphonic acid monoester; and treating the portion of the subterranean formation. Methods of fracturing, providing some degree of sand control, cleaning a portion of a pipeline, treatment fluid compositions, and difunctional gelling agent compositions also are provided.

Abstract: The present invention relates to compositions and methods for the treatment of prostate cancer. In certain embodiments, the invention relates to compositions and methods for the inhibition of prostate cancer cell growth, comprising inhibiting the activity of Stat5 in prostate cancer cells.

Abstract: The present invention relates to the preparation and biological activity of 3-deoxy-Dmyo-inositol ether lipid analogs as inhibitors of phosphatidylinositol-3-kinase signaling and cancer cell growth. The compounds of the present invention are useful as anti-tumor 5 agents which effectively inhibit the growth of mammalian cells.

Abstract: The invention relates to a novel method and kit for detecting and measuring pleiotrophin in samples and diagnosing pleiotrophin-positive diseases. The method involves incubating a sample suspected of containing PTN with anti-PTN antibodies and determining the presence of PTN using a sandwich ELISA. Also methods for treating a pleiotrophin-positive disease by administering an anti-PTN antibody or fragment thereof are provided.

Abstract: The invention provides a SHINC-2 polynucleotide, which can be a nucleic acid encoding all or a portion of a SHINC-2 protein, or a complementary polynucleotide or antisense polynucleotide. The invention provides a SHINC-2 polypeptide, which can be a full-length SHINC-2 protein or a fragment thereof or an analog or homolog thereof. Desirably, the SHINC-2 polypeptide modulates apoptosis. The invention provides an antibody that specifically binds a SHINC-2 polypeptide. The invention provides diagnostic methods. For example, the invention affords a method for identifying compounds that modulate apoptosis. The invention provides a method for detecting or evaluating the prognosis of a cancer. The invention provides diagnostic compositions for detection of cancer. The invention provides a method of modulating apoptosis or treating or preventing a cancer, tumor growth and/or metastasis by administration of an agent that modulates the expression and/or activity of SHINC-2.

Abstract: The present invention relates to a method for creating two- and three-dimensional arrays. Plates of sample materials are stacked to create primary stacks. Primary stacks are sliced to form combs. Combs are stacked to form secondary stacks. Secondary stacks are sliced to form tertiary plates or two-dimensional arrays. Tertiary plates can be stacked to form three-dimensional arrays. The two- and three-dimensional arrays can be used in large-scale parallel processing of samples, pattern printing, tissue engineering, microfluidics, microelectronics, and microconstruction.

Abstract: A method of detecting an enzyme-mediated DNA cleavage reaction in a fluorometric assay is provided. The method can be used to detect DNA cleavage caused by restriction endonucleases, retroviral integrase enzymes, DNases, RNases, or enzymes utilized in other strand separating processes in molecular biology.

Abstract: In certain aspects, the present invention relates to methods and preparations for treating angiotensin II-mediated diseases, and in particular, methods of screening for agents that modulate post-transcriptional regulation of angiotensin II receptors and the use of such agents.

Abstract: The present invention is directed to the use of the extract of Ginkgo biloba leaves or isolated Ginkgolide B (GKB), a component of the extract of Ginkgo biloba leaves in a method for decreasing the expression of peripheral-type benzodiazepine receptor (PBR) in cells of a patient in need thereof. Further, the present invention is directed to the use of the extract of Ginkgo biloba leaves or isolated GKB in a method for decreasing the proliferation of cancer cells in a patient. More particularly, the present invention is directed to the use of the extract of Ginkgo biloba leaves or isolated GKB in a method of decreasing cancer cell proliferation in a patient wherein the cancer cell is human breast cancer cell.

Abstract: The present invention relates to methods for inducing cell death via activation of the caspase, SAPK, and apoptotic signaling cascades in a cell comprising administering to a cell a composition comprising tempo in a amount sufficient to induce death of said cell.

Abstract: It is possible to radiosensitize tumor cells by administration of compositions containing the Human antisense c-raf-1 oligodeoxyribonucleotide (ODN/oligo) sequence: 5?-GTGCTCCATTGATGC-3? (SEQ. ID. NO: 1) wherein only the end bases are phosphorothioated is a preferred embodiment. Antisense sequences of up to 40 bases which contain this sequence, such as 5?-CCTGTATGTGCTCCATTGATGCAGC-3? (SEQ ID NO: 2) may be used in accord with the teachings of this disclosure. Compositions comprising a cationic liposome of dimethyldioctadecyl ammonium bromide, phosphatidylcholine and cholesterol may be used as a carrier system. The liposomes provide a new carrier system that is particularly useful for administration of sequences for therapy.

Abstract: The present invention relates to a novel HLF protein which is a member of the heregulin family. In particular, isolated nucleic acid molecules are provided encoding the human HLF protein. HLF polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of HLF activity. Also provided are diagnostic methods for detecting disorders of the regulation of cell growth and therapeutic methods for treating disorders of the regulation of cell growth.

Abstract: A new gene therapy entails tumor treatment by introducing an expressible nucleotide sequence for a soluble costimulatory factor, thereby enhancing the response of T-cells to a tumor. In vivo expression of the soluble factor overcomes anergy or tolerance to tumor cells and activates T-cells that are infiltrating or surrounding the tumor. A pharmaceutical composition containing such a gene is effective in tumor suppression.